Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany

被引：2

作者：

Althoff, F. C. ^{[1
]}

Stratmann, J. A. ^{[1
]}

Doebel, P. ^{[1
]}

Hunerlituerkoglu, A. N. ^{[2
]}

Frost, N. ^{[3
,4
]}

Christopoulos, P. ^{[5
]}

Zum Bueschenfelde, C. Meyer ^{[6
]}

Alt, J. ^{[7
]}

Webendoerfer, M. ^{[8
]}

Kaldune, S. ^{[9
]}

Tritchkova, G. ^{[10
]}

Waller, C. F. ^{[11
]}

Braess, J. ^{[12
]}

Kopp, H-G. ^{[13
]}

Grohe, C. ^{[14
]}

Schumann, C. ^{[15
]}

Griesinger, F. ^{[16
]}

Kuon, J. B. ^{[17
]}

Sebastian, M.

Reinmuth, N. ^{[18
]}

机构：

[1] Johannes Wolfgang Goethe Univ, Haematol Oncol, Univ Klinikum Frankfurt, Frankfurt, Germany

[2] Helios Klinikum Krefeld, Hematol Oncol, Krefeld, Germany

[3] Univ Klin, Dept Infect Dis & Pneumonol, Berlin, Germany

[4] Charite Campus Virchow Klinikum, Berlin, Germany

[5] Thoraxklin Heidelberg gGmbH, Dept Oncol Thorac Tumors, Heidelberg, Germany

[6] ViDia Karlsruhe Diakonissenkrankenhaus, Hematol Oncol, Karlsruhe, Germany

[7] Univ Med Mainz, Med Klin Poliklin 3, Mainz, Germany

[8] Univ Klinikum Essen, Med Oncol, Essen, Germany

[9] RoMed Klinikum Rosenheim, Med Klin, Rosenheim, Germany

[10] Tech Univ Dresden, Internal Med, Carl Gustav Carus Fac Med, Dresden, Germany

[11] Univ Klinikum Freiburg, Hematol Oncol & Stem Cell Transplantat, Klin Innere Med Hamatol Onkol & Stammzelltranspla, Freiburg, Germany

[12] St John Gods Hosp, Hematol Med Oncol, Regensburg, Germany

[13] Robert Bosch Kran Kenhaus, Dept Hematol Oncol, Stuttgart, Germany

[14] ELK Berlin Chest Hosp, Pneumol, Evangel Lungenklin, Berlin, Germany

[15] Klinikum Kempten Oberallgaeu gGmbH, Klin Pneumol Thoraxonkol Schlaf & Beamtungsmed, Kempten, Germany

[16] Pius Hosp, Dept Oncol, Oldenburg, Germany

[17] SLK Kliniken Heilbronn GmbH, Thorac Oncol Dept, Heilbronn, Germany

[18] Asklepios Fachklinikum, Thorac Oncol, Gauting, Germany

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2437

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1405P

引用

页数：1

共 50 条

[21] Sotorasib in KRAS G12C-mutated advanced non-small cell lung cancer (aNSCLC): Overall survival (OS) data from the global expanded access program (EAP study-436)
Novello, S.
Maimon, N.
Stevenson, J. P.
Petty, W.
Ferreira, C. G. M.
Morbeck, I.
Zer, A.
Bauman, J. R.
Kalmadi, S.
Xia, C.
Meloni, A.
Varrieur, T.
Awad, M.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S40 - S41
[22] Prolonged Cancer Control With Adagrasib in Patients With Metastatic, KRAS G12C-Mutated NSCLC After Sotorasib-Induced Hepatotoxicity: A Case Report
Stratton, Natalie
Thompson, Jonathan
JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (04):
[23] Use of sotorasib in KRAS p. G12C mutated NSCLC: a case report
Barot, Hasti
Evans, Joanne
Mohammed, Waleed
Power, Danielle
LUNG CANCER, 2022, 165 : S77 - S77
[24] Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study
Wislez, M.
Mascaux, C.
Cadranel, J.
Thomas, Q. D.
Ricordel, C.
Swalduz, A.
Pichon, E.
Veillon, R.
Gounant, V.
Rousseau-Bussac, G.
Madroszyk, A.
Daniel, C.
Ravoire, M.
Metivier, A. -C
Fournel, P.
Missy, P.
Morin, F.
Guisier, F.
Westeel, V.
EUROPEAN JOURNAL OF CANCER, 2025, 219
[25] Sotorasib Shows Intracranial Activity in Patients with KRAS G12C-Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases
Koster, Kira-Lee
Appenzeller, Christina
Lauber, Arno
Fruh, Martin
Schmid, Sabine
CASE REPORTS IN ONCOLOGY, 2022, 15 (02): : 720 - 725
[26] Prognostic implication of KRAS G12C mutation in a real-world KRAS mutated stage IV NSCLC cohort treated with immunotherapy in the Netherlands
Noordhof, Anneloes L.
Swart, Esther M.
Damhuis, Ronald A. M.
Hendriks, Lizza E. L.
Kunst, Peter W. A.
Aarts, Mieke J.
Van Geffen, Wouter H.
EUROPEAN RESPIRATORY JOURNAL, 2023, 62
[27] Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
Noordhof, Anneloes L.
Swart, Esther M.
Damhuis, Ronald A. M.
Hendriks, Lizza E. L.
Kunst, Peter W. A.
Aarts, Mieke J.
van Geffen, Wouter H.
JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (09):
[28] Sotorasib with panitumumab in chemotherapy-refractory KRAS G12C-mutated colorectal cancer: a phase 1b trial
Kuboki Y.
Fakih M.
Strickler J.
Yaeger R.
Masuishi T.
Kim E.J.
Bestvina C.M.
Kopetz S.
Falchook G.S.
Langer C.
Krauss J.
Puri S.
Cardona P.
Chan E.
Varrieur T.
Mukundan L.
Anderson A.
Tran Q.
Hong D.S.
Nature Medicine, 2024, 30 (1) : 265 - 270
[29] NURSING EXPERIENCE WITH PATIENTS RECEIVING SOTORASIB FOR KRAS G12C-MUTATED SOLID TUMORS: FOLLOW-UP FROM THE PHASE 1/2 CODEBREAK 100 STUDY
Dozier, Askia
Fitzpatrick, Victoria
Liu, Dazhi
Hull, Jennifer
Varrieur, Tracy
McGuire, Lauren
ONCOLOGY NURSING FORUM, 2022, 49 (02) : 22 - 23
[30] COST PER RESPONDER ANALYSIS COMPARING ADAGRASIB AND SOTORASIB IN PATIENTS WITH KRAS G12C-MUTATED PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (NSCLC)
Berardi, A.
Laurie, M.
Theriou, C.
Orsini, I
Bouwmeester, W.
Gao, S.
Korytowsky, B.
VALUE IN HEALTH, 2023, 26 (12) : S119 - S120

← 1 2 3 4 5 →